Showing 49,321 - 49,340 results of 226,904 for search '(( a ((step decrease) OR (a decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 2.09s Refine Results
  1. 49321

    Image_2_Suicide risk among female breast cancer survivors: A population–based study.tif by Jian Shi (141852)

    Published 2022
    “…Female breast cancer survivors had a higher risk of suicide than the general population (SMR = 1.19; 95% CI (1.08–1.31)). …”
  2. 49322
  3. 49323

    Impact of body mass index on growth hormone stimulation tests in children and adolescents: a systematic review and meta-analysis by Ozair Abawi (8816267)

    Published 2021
    “…Pubertal status, presence of syndromic obesity, mean age, and mean BMI SDS did not moderate the pooled <i>r</i> (all <i>p</i> > 0.05). Individual participant data analysis revealed a beta of −0.123 (95% CI −0.160 to −0.086, <i>p</i> < 0.0001), i.e. per one-point increase in BMI SDS, peak GH decreases by 11.6% (95% CI 8.3–14.8%). …”
  4. 49324

    DataSheet1_Ambient Air Quality Standards and Policies in Eastern Mediterranean Countries: A Review.docx by Sasan Faridi (9277880)

    Published 2023
    “…We estimated that the reduction of annual mean PM<sub>2.5</sub> exposure level to the AQG level (5 μg m<sup>−3</sup>) would be associated with a decrease of all natural-cause mortality in adults (age 30+) by 16.9%–42.1% in various EMR countries. …”
  5. 49325

    Operons with an upstream FNR ChIP-seq peak and a FNR-dependent change in expression under GMM. by Kevin S. Myers (424665)

    Published 2013
    “…Each operon was determined to have a significant (>2 fold) increase (+), decrease (−) and no change (o) in WT −O<sub>2</sub> relative to WT +O<sub>2</sub> (<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003565#pgen.1003565.s018" target="_blank">Table S12</a>).…”
  6. 49326

    UBKIs possess broad antiviral activity, are effective in primary cells, and impose a barrier against resistance development. by Markus Lesch (6475409)

    Published 2019
    “…The calculation of p-values revealed a significant decrease of log-transformed virus-titers in the regorafenib and sorafenib-treated groups relative to the DMSO control at the indicated time points: *: p-value ≤ 0.05. …”
  7. 49327

    Gene set enrichment analysis revealed NF-κB signaling as a potential downstream regulator of Efp. by Wataru Sato (149080)

    Published 2018
    “…(<b>D</b> and <b>E</b>) Decrease of <i>IL6ST</i> and <i>IL18</i> mRNA levels in siEfp #A-treated tumors <i>in vivo</i>. …”
  8. 49328
  9. 49329
  10. 49330

    Removal of aggregates by chaperones rescue expression pattern of micoRNAs, p53 and RelA/NFkB. by Jayeeta Ghose (207861)

    Published 2011
    “…<p>(<b>A</b>) RT-PCR showing increase in p53 expression in ST<i>Hdh<sup>Q7</sup>/Hdh<sup>Q7</sup></i> cells co-transfected with 83Q DsRed and empty vector GFP-C1 (lane ii, n = 3, p = 0.028) and decrease in p53 expression in ST<i>Hdh<sup>Q7</sup>/Hdh<sup>Q7</sup></i> cells co-transfected with 83Q DsRed and Hsp70-GFP (lane iii, n = 3, p = 0.025) and 83Q DsRed and HYPK-GFP (lane iv, n = 3, p = 0.019) compared to control ST<i>Hdh<sup>Q7</sup>/Hdh<sup>Q7</sup></i> cells (lane i). …”
  11. 49331

    H<sub>2</sub>BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy by Karthika J. Kadassery (6852422)

    Published 2022
    “…Actinium-225 (<sup>225</sup>Ac) is one of the most promising radionuclides for targeted alpha therapy (TAT). With a half-life of 9.92 days and a decay chain that emits four high-energy α particles, <sup>225</sup>Ac is well-suited for TAT when conjugated to macromolecular targeting vectors that exhibit extended in vivo circulation times. …”
  12. 49332

    H<sub>2</sub>BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy by Karthika J. Kadassery (6852422)

    Published 2022
    “…Actinium-225 (<sup>225</sup>Ac) is one of the most promising radionuclides for targeted alpha therapy (TAT). With a half-life of 9.92 days and a decay chain that emits four high-energy α particles, <sup>225</sup>Ac is well-suited for TAT when conjugated to macromolecular targeting vectors that exhibit extended in vivo circulation times. …”
  13. 49333

    Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial by Xavier Duval (134550)

    Published 2010
    “…</p><h3>Trial registration</h3><p><a href="http://www.ClinicalTrials.gov">www.ClinicalTrials.gov</a><a href="http://www.clinicaltrials.gov/ct2/results?…”
  14. 49334

    H<sub>2</sub>BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy by Karthika J. Kadassery (6852422)

    Published 2022
    “…Actinium-225 (<sup>225</sup>Ac) is one of the most promising radionuclides for targeted alpha therapy (TAT). With a half-life of 9.92 days and a decay chain that emits four high-energy α particles, <sup>225</sup>Ac is well-suited for TAT when conjugated to macromolecular targeting vectors that exhibit extended in vivo circulation times. …”
  15. 49335

    <sup>68</sup>Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity by Jothilingam Sivapackiam (651201)

    Published 2019
    “…Employing the fluorescent traits of Galmydar, live cell fluorescence imaging indicated a gradual decrease in uptake and retention of Galmydar within mitochondria of H9c2 cells following DOX-treatment, while indicating dose-dependent and time-dependent uptake profiles. …”
  16. 49336

    A High Throughput Genetic Screen Identifies New Early Meiotic Recombination Functions in <em>Arabidopsis thaliana</em> by Arnaud De Muyt (259493)

    Published 2009
    “…A collection of 55,000 mutant lines was screened, and <em>spo11</em>-like mutations, characterised by a drastic decrease in chiasma formation at metaphase I associated with an absence of synapsis at prophase, were selected. …”
  17. 49337
  18. 49338

    Data from population B analyzed for this report. by Birgit Deboutte (19452787)

    Published 2024
    “…In population A, when two parents were screened with the VMBDD compared to one, there was an average LI decrease of 0.03 (P<0.05). …”
  19. 49339
  20. 49340

    Legend for supporting information S2–S5. by Birgit Deboutte (19452787)

    Published 2024
    “…In population A, when two parents were screened with the VMBDD compared to one, there was an average LI decrease of 0.03 (P<0.05). …”